Laboratory Core

项目摘要/摘要 撒哈拉以南非洲感染艾滋病毒的人对恶性肿瘤的易感性增加，即使在 这些人正在接受抗逆转录病毒治疗(ART)，并已完全抑制HIV-1病毒在 外周血液。了解和减少这种癌症风险增加的基础是关键的下一步 改善生活质量，减轻该地区卫生管理的经济负担 艾滋病的流行。在非洲，癌症很大程度上是由传染病引起的。子宫颈鳞状细胞瘤 在非洲，头和脖子，特别是眼睛，与艾滋病毒-1感染有关，并可能导致 与人乳头瘤病毒(HPV)混合感染。同样，最常见的卡波西肉瘤(KS) 赞比亚男性中的艾滋病毒相关恶性肿瘤和赞比亚第三大艾滋病毒相关恶性肿瘤 女性，由卡波西肉瘤疱疹病毒(KSHV)/人类疱疹病毒-8(HHV-8)引起。因此，高 由KSHV引起的发病率癌症，以及可能由HPV引起的癌症，在艾滋病毒-1共同感染的人群中发生的频率更高。 似乎正在通过抗逆转录病毒疗法控制艾滋病毒-1疾病的感染者。为了更有效地治疗 对于这些恶性肿瘤，研究人员需要了解为什么会发生这种情况。赞比亚艾滋病的目标 恶性肿瘤诊断与发病计划S实验室的核心是提供完整的分子、 与ZAMDAPP的生物统计和流行病学核心并行的免疫学、诊断支持 财团资助的研究项目和培训举措，并进一步发展能力和基础设施 在赞比亚进行癌症研究。为了实现这一目标，核心将1)建立和移交 支持早期KS诊断和HPV检测的分子程序；2)开发有效的标本 档案，再加上计算机化的信息存储，以促进共享交换和分析管道 获取研究数据；以及3)提供或促进培训机会，以增加基本研究技能和 对艾滋病毒相关恶性肿瘤研究感兴趣的赞比亚人的能力。核心将由以下人员组成 经验丰富的多学科基础科学家和临床实验室科学家，将有两个运作中心： 一个在赞比亚卢萨卡的大学教学医院，一个在美国的卢萨卡大学。 内布拉斯加州-林肯。

PROJECT SUMMARY/ABSTRACT Sub-Saharan Africans living with HIV infection experience enhanced susceptibility to malignancies even when the individuals are on anti-retroviral therapy (ART) and have fully suppressed HIV-1 viral replication in the peripheral blood. Understanding and reducing the bases of this enhanced cancer risk is a critical next step to improve the quality of life and reduce the economic burden of health management in this region devastated by the AIDS epidemic. In Africa, cancers largely result from infectious etiologies. Squamous cell neoplasias of the head and neck, and particularly those of the eye, are associated with HIV-1 infection in Africa and may result from co-infection with human papilloma viruses (HPV). Likewise, Kaposi’s sarcoma (KS), the most common HIV-associated malignancy in Zambian men and the third leading HIV-associated malignancy in Zambian women, is caused by Kaposi’s Sarcoma Herpesvirus (KSHV)/Human Herpesvirus-8 (HHV-8). Thus, high incidence cancers caused by KSHV, and potentially by HPV, are occurring at higher frequencies in HIV-1 co- infected individuals who appear to be controlling HIV-1 disease through ART. In order to more effectively treat these malignancies, researchers need to understand why this is occurring. The goal of the Zambian AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)’s Lab Core is to provide integrated molecular, immunological, and diagnostic support in parallel with ZAMDAPP’s Biostatistics and Epidemiology Core for the consortium-funded research projects and training initiatives, and to further develop capacity and infrastructure to conduct cancer research in Zambia. To accomplish this goal, the core will 1) establish and transfer molecular procedures in support of early KS diagnosis and HPV detection; 2) develop an effective specimen archive, coupled with computerized information storage, to facilitate sharing exchange and analyses pipelines for study data; and 3) provide or facilitate training opportunities to increase essential research skills and capacities for Zambians with interests in HIV-associated malignancy research. The core will be staffed by experienced multidisciplinary basic scientists and clinical lab scientists and will have two hubs of operation: one at the University Teaching Hospital in Lusaka, Zambia and one in the United States at the University of Nebraska-Lincoln.